Patients and study design
ONCOLOGY, WEST, DISEASE
The prospective study was designed to be an open‐label, noninterventional, observational study in real‐world clinical practice, detailing how to optimize and stratify the use of current therapy regimens for elderly patients with NDMM (chiCTR2000029925). NDMM patients 65 years old and above were sequentially recruited between January 1, 2017 and April 1, 2021 and followed until July 10, 2021. This study was approved by the Ethics Committee of West China Hospital, Sichuan University (WCHSCU). All subjects provided written informed consent.The inclusion criteria were previously untreated and symptomatic MM patients 65 years of age or older and ineligible for hematopoietic stem cell transplantation. The exclusion criteria included patients participating in other clinical trials. In addition, detailed baseline clinical data were collected, including Eastern Cooperative Oncology Group (ECOG) performance status, disease stage, and laboratory test results. The definition of the high cytogenetic risk group was in accordance with the IMWG definition,